Kennedy Capital Management LLC Trims Stock Position in Agilent Technologies, Inc. (NYSE:A)

Kennedy Capital Management LLC lowered its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 23.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,857 shares of the medical research company's stock after selling 21,158 shares during the quarter. Kennedy Capital Management LLC's holdings in Agilent Technologies were worth $9,385,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. Flynn Zito Capital Management LLC lifted its stake in shares of Agilent Technologies by 3.8% during the fourth quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company's stock worth $251,000 after purchasing an additional 69 shares in the last quarter. IFP Advisors Inc lifted its stake in shares of Agilent Technologies by 17.7% in the 4th quarter. IFP Advisors Inc now owns 458 shares of the medical research company's stock worth $62,000 after acquiring an additional 69 shares during the period. Tiemann Investment Advisors LLC raised its position in Agilent Technologies by 5.6% in the fourth quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company's stock worth $191,000 after acquiring an additional 75 shares in the last quarter. Rothschild Investment LLC grew its holdings in shares of Agilent Technologies by 19.2% in the 4th quarter. Rothschild Investment LLC now owns 491 shares of the medical research company's stock worth $66,000 after acquiring an additional 79 shares during the last quarter. Finally, CIBC Private Wealth Group LLC raised its stake in Agilent Technologies by 1.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 7,479 shares of the medical research company's stock valued at $1,025,000 after purchasing an additional 87 shares during the period.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have commented on the stock. TD Cowen increased their target price on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Thursday, April 10th. Robert W. Baird lowered their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Citigroup boosted their price objective on shares of Agilent Technologies to $165.00 and gave the company a "buy" rating in a research report on Thursday, December 19th. StockNews.com upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, December 24th. Finally, Barclays lowered their target price on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $146.25.

Insider Activity

In other news, Director Daniel K. Podolsky sold 1,819 shares of the company's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $116.46, for a total transaction of $211,840.74. Following the completion of the transaction, the director now directly owns 35,737 shares of the company's stock, valued at approximately $4,161,931.02. This represents a 4.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Padraig Mcdonnell sold 1,911 shares of the business's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now directly owns 39,652 shares of the company's stock, valued at $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,638 shares of company stock worth $731,229 over the last 90 days.

Agilent Technologies Trading Up 0.3 %

Shares of NYSE:A traded up $0.30 during trading on Wednesday, hitting $103.42. The company had a trading volume of 547,261 shares, compared to its average volume of 2,068,973. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. The stock has a market cap of $29.49 billion, a price-to-earnings ratio of 23.77, a price-to-earnings-growth ratio of 2.96 and a beta of 1.19. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $155.35. The company has a fifty day simple moving average of $122.01 and a two-hundred day simple moving average of $133.33.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. The firm had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. As a group, equities analysts forecast that Agilent Technologies, Inc. will post 5.55 earnings per share for the current year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be paid a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a dividend yield of 0.96%. The ex-dividend date of this dividend is Tuesday, April 1st. Agilent Technologies's payout ratio is 22.76%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.